CES1 and hepatocellular carcinoma: In our study, we found that blockage of CES1 led to alterations in cisplatin resistance–related factors, including PUFAs, SCD, and ACC1, thereby interfering with lipid metabolism and sensitizing HCC to cisplatin treatment.